Interim analysis of vaccine by Pfizer/BioNTech far exceeds expectations of most experts
A vaccine against Covid-19 is in sight, with the announcement of the first interim results in large-scale trials showing the Pfizer/BioNTech candidate is 90% effective, according to the manufacturers, whose analysis shows a much better performance than most experts had hoped for.
The high percentage of those protected makes the findings compelling. Regulators have said they would approve a vaccine that is just 50% effective – protecting half those who get it. The company says there have been no serious side-effects.
“Today is a great day for science and humanity. The first set of results from our phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” said Dr Albert Bourla, the Pfizer chairman and CEO.